Cost-effectiveness analysis of AS04-adjuvanted human papillomavirus 16/18 vaccine compared with human papillomavirus 6/11/16/18 vaccine in the Philippines, with the new 2-dose schedule

• Главные авторы: Maria Julieta Germar (Автор), Carrie Purugganan (Автор), Ma. Socorro Bernardino (Автор), Benjamin Cuenca (Автор), Y-Chen Chen (Автор), Xiao Li (Автор), Georges Van Kriekinge (Автор), I-Heng Lee (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2017-05-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Cervical cancer (CC) is the second leading cause of cancer death among Filipino women. Human papillomavirus (HPV) vaccination protects against CC. Two vaccines (AS04-HPV-16/18 and 4vHPV) are approved in the Philippines; they were originally developed for a 3-dose (3D) administration and have recentl...